Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
18 déc. 2024 08h30 HE
|
Coherus BioSciences, Inc.
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
03 déc. 2024 07h00 HE
|
Coherus BioSciences, Inc.
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor - - Proceeds to fund...
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
27 nov. 2024 16h01 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
06 nov. 2024 16h01 HE
|
Coherus BioSciences, Inc.
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
30 oct. 2024 16h20 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h05 HE
|
Coherus BioSciences, Inc.
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as...
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
01 août 2024 09h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after...
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
27 juin 2024 08h26 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
05 juin 2024 09h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice...
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
30 mai 2024 09h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare...